1月15日 的 actiTENS 應用程式分析
actiTENS
- SUBLIMED
- Apple App Store
- 免費版
- 醫療
actiTENS is a transcutaneous electrical nerve stimulator (TENS), operated via a mobile application and based on the TENS principle to relieve pain in adults.
Back to an Active Life
Specifically designed to offer an ergonomic and discreet solution, the device adapts to various body types and different areas of the body and can be worn under clothing. actiTENS comes with a wide range of accessories, including specialized electrodes and various fastening supports, all designed to optimize pain management during daily activities.
One app, two functions
The actiTENS app is a personalised treatment tool that allows users to both control the device via the integrated remote control function and access the list of programmes. The app also serves as a therapy monitoring tool through the “My Health” menu, and supports mobility tracking thanks to the built-in pedometer.
Patient Account Creation and Cloud Security
For an even more personalized experience, actiTENS offers the option to create a patient account. This account not only saves preferences and tracking data in a secure cloud. Creating an account ensures information portability, regardless of the smartphone used. This functionality ensures continuity in treatment monitoring, promoting optimal care.
Recommendation from Healthcare Professionals
Despite the customization available through the application, consulting a healthcare professional is recommended. This ensures proper electrode placement and the selection of programmes most suitable for each user's specific situation.
actiTENS represents a innovative and discreet solution for pain management. With the integration of a pedometer and the option to create a patient account, it provides a comprehensive approach to well-being while ensuring the security and continuity of treatment monitoring.
商店排名
商店排名基於Google和Apple設定的多個參數。
所有類別 在
美國--
醫療 在
美國--
建立帳戶即可查看平均每月下載次數聯絡我們
隨時間變化的 actiTENS 排名統計
Similarweb 的使用排名和Apple App StoreactiTENS排名
排名
無可用數據
1月 15, 2026